beclabuvir (BMS-791325) / BMS |
NCT02045966: Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects |
|
|
| Completed | 1 | 16 | US | Cocktail, DCV 3DAA FDC, BMS-791325 | Bristol-Myers Squibb | Hepatitis C | 04/14 | 04/14 | | |
| Completed | 1 | 32 | US | Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone | Bristol-Myers Squibb | Hepatitis C | 04/14 | 04/14 | | |
| Completed | 1 | 8 | Europe | BMS-791325, [13C]-BMS-791325 | Bristol-Myers Squibb | Hepatitis C Virus Infection | 05/14 | 05/14 | | |
NCT02104843: Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin |
|
|
| Completed | 1 | 18 | US | Daclatasvir, Asunaprevir and BMS-791325 FDC, BMS-791325, Rosuvastatin, Crestor® | Bristol-Myers Squibb | Hepatitis C | 05/14 | 05/14 | | |
NCT02084953: Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects |
|
|
| Completed | 1 | 59 | US | BMS-791325, Moxifloxacin, Avelox®, Placebo matching BMS-791325 | Bristol-Myers Squibb | Hepatitis C | 05/14 | 05/14 | | |
NCT02108639: To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet |
|
|
| Completed | 1 | 41 | US | DCV 3DAA FDC, Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325, BMS-791325 | Bristol-Myers Squibb | Hepatitis C | 06/14 | 06/14 | | |
NCT02103569: Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325 |
|
|
| Completed | 1 | 20 | US | FDC of Daclatasvir, Asunaprevir and BMS-791325, FDC of Norethindrone and Ethinyl Estradiol, Loestrin®, BMS-791325 | Bristol-Myers Squibb | Hepatitis C | 07/14 | 07/14 | | |
NCT02175602: Study of Drug Combination on Pharmacokinetics in Healthy Volunteers |
|
|
| Completed | 1 | 41 | US | Escitalopram, Lexapro, Sertraline, Zoloft, DCV 3DAA FDC, BMS-791325 | Bristol-Myers Squibb | Hepatitis C Infection | 08/14 | | | |
NCT00947245: Japanese Bridging Study Conducted in the United States |
|
|
| Withdrawn | 1 | 0 | US | BMS-791325, Placebo | Bristol-Myers Squibb | Hepatitis C Virus | 02/15 | 02/15 | | |